| 摘要 |
<p>Disclosed is a marker for predicting the prognosis of pancreatic cancer recurrence including proteins selected from the group consisting of alpha-2-antiplasmin, lumican, apolipoprotein CIII, alpha-2-macroglobulin, complement C4 gamma chain, lamin A/C, elongation factor Tu, triosephosphate isomerase, and carbonic anhydrase V. By the present invention, the proteins known to be specifically overexpressed or downregulated in the serum of patients with recurrent pancreatic cancer after surgical treatment can be useful as a biomarker for predicting the prognosis of pancreatic cancer recurrence before concurrent chemoradiotherapy.</p> |
